 |
| 충북 오송 펩트론 공장 전경. (사진=펩트론) |
[Alpha Biz= Kim Jisun] Peptron announced on December 1 that its platform technology evaluation agreement with Eli Lilly, originally expected to conclude by December 7, 2024, has been extended to October 7, 2026. Following the disclosure, Peptron’s share price fell 18% in after-hours trading.
Peptron signed the “Platform Technology Evaluation Agreement” with Eli Lilly on October 7, 2024, initiating joint research to apply its long-acting SmartDepot platform to Lilly’s peptide drug portfolio under a non-exclusive license. The agreement called for up to 14 months of evaluation, after which the parties could proceed to a full licensing contract.
The contract value exceeded 10% of Peptron’s annual revenue at the time, placing it under mandatory disclosure rules; however, the amount remains undisclosed at Lilly’s request until October 7, 2034. Peptron’s revenue was KRW 3.3 billion in 2023 and KRW 3.1 billion in 2024.
Despite the extension, Peptron stated that joint research and technical evaluation are progressing smoothly. The two companies recently agreed to conduct additional in-vivo studies on a specific peptide’s SmartDepot formulation, which is expected to lengthen the overall evaluation timeline beyond the initially planned 14 months.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
